SMARTDRUGENTITIES

Sophisticated Well-Targeted Therapeutic Entities based on Biologically Compatible Ti(IV) Active Cores and Building Blocks

Coordinatore	THE HEBREW UNIVERSITY OF JERUSALEM.    more Spiacenti, non ci sono informazioni su questo coordinatore. Contattare Fabio per maggiori infomrazioni, grazie.
Nazionalità Coordinatore	Israel [IL]
Totale costo	1˙400˙000 €
EC contributo	1˙400˙000 €
Programma	FP7-IDEAS-ERC Specific programme: "Ideas" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	ERC-2009-StG
Funding Scheme	ERC-SG
Anno di inizio	2009
Periodo (anno-mese-giorno)	2009-10-01   -   2014-09-30

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	THE HEBREW UNIVERSITY OF JERUSALEM.  Organization address address: GIVAT RAM CAMPUS city: JERUSALEM postcode: 91904 contact info Titolo: Dr. Nome: Edit Cognome: Tshuva (Goldberg) Email: send email Telefono: 97226586084 Fax: 97226584282	IL (JERUSALEM)	hostInstitution	1˙400˙000.00
2	THE HEBREW UNIVERSITY OF JERUSALEM.  Organization address address: GIVAT RAM CAMPUS city: JERUSALEM postcode: 91904 contact info Titolo: Ms. Nome: Hani Cognome: Ben-Yehuda Email: send email Telefono: +972 2 6586676 Fax: +972 2 6513205	IL (JERUSALEM)	hostInstitution	1˙400˙000.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'I propose to develop sophisticated anti-tumor agents targeted particularly to the location of activity. My team has recently introduced a new family of Ti(IV) complexes that demonstrates higher activity than known compounds with substantially higher stability and defined hydrolytic behavior, properties that were found to be essential. I propose to study various derivatives and identify the parameters affecting activity, including steric and electronic effects, enantiomeric purity, ligand lability etc., and elucidation various mechanistic aspects of reactivity. More importantly, I propose to construct pH-sensitive transport units that will allow protection of the sensitive active species throughout their delivery and release only near the target location based on the variable pH conditions of different human tissues. In particular, unique spherical molecules held together by metal-ligand interactions will be prepared. The building blocks will consist of the planar ligands of C3-axis bound to three biocompatible Ti(IV) ions each with defined angles and geometry. The resulting spherical compounds will be utilized to encapsulate the active complexes and release them upon hydrolysis at the desired pH based on the pH-dependent hydrolysis pattern already established for related compounds. Preliminary calculations have confirmed the possibility of forming these compounds, which are particularly matching in their expected size to encapsulate our complexes. Larger spheres will also be prepared as cavities for larger molecules, which may be linked together for the delivery of multiple drugs. These compounds may find applications in various areas where a protected environment or delivery of sensitive compounds is required, such as in gene therapy, nano-technology, and catalysis.'